Copyright © Queen's Printer,
Victoria, British Columbia, Canada
Licence
Disclaimer
Volume 65, No. 8
106/2022
The British Columbia Gazette, Part II
April 26, 2022

B.C. Reg. 106/2022, deposited April 19, 2022, under the PHARMACY OPERATIONS AND DRUG SCHEDULING ACT [section 22 (1)]. Resolution of the Board of the College of Pharmacists of British Columbia, dated February 11, 2022.

Resolution of the Board of the College of Pharmacists of British Columbia made the 11th day of February, 2022.

RESOLVED THAT, in accordance with the authority established in section 22 (1) of the Pharmacy Operations and Drug Scheduling Act, and subject to filing with the Minister as required by section 22 (2) of the Pharmacy Operations and Drug Scheduling Act, the board amend the Drug Schedules Regulation, B.C. Reg. 9/98, as set out in the schedule attached to this resolution.

— S. SOLVEN, R.Ph., Registrar and CEO.

Appendix

1 The Drug Schedules Regulation, B.C. Reg. 9/98, is amended in the Schedules

(a) by striking out the following:

2 Acetylcysteine

2 Allethrins (pyrethrins)

1 Alverine and its salts (for parenteral use)

1 Amino acid solutions (for parenteral use)

2 Arginine and its salts

2 Artemisia, its preparations, extracts and compounds (except in trace amounts in homeopathic preparations)

2 Belladonna alkaloids, and their salts and derivatives (except in preparations for topical use or in trace amounts in homeopathic preparations)

2 Benzocaine and its salts (for parenteral or ophthalmic use)

2 Benzyl benzoate

3 Bisacodyl and its salts except when sold in

(a) concentrations of 5 mg or less per oral dosage unit or 10 mg or less per rectal dosage unit/suppository, and

(b) package sizes containing no more than 50 mg of bisacodyl

2 Boric acid and its salts (in preparations for systemic use, or ophthalmic preparations in concentrations of greater than 2%) [Note: does not apply to contact lens solutions intended to be rinsed off prior to placement of lens on the eye]

2 Camphor (in oleaginous vehicles and in liquid forms in concentrations greater than 11%)

2 Cantharides, their preparations and derivatives

2 Choline bitartrate (parenteral)

2 Chymopapain (parenteral)

2 Chymotrypsin (parenteral and ophthalmic)

2 Dextrose (sclerosing agents)

1 Epinephrine and its salts (other than in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens)

2 Esdepallethrin/piperonyl butoxide

2 Heparin and its salts (except for topical use)

2 Histamine and its salts (except for topical use)

2 Hyaluronic acid and its salts (preparations in concentrations of 5% or more)

2 Hyaluronidase

1 Hydrocortisone or hydrocortisone acetateV (except when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin, for adults and children 2 years of age and over, and in package sizes containing no more than 30 g)

1 Hydroquinone or its derivatives, when sold in a concentration greater than 2% in preparations for topical use on the skin

2 Hydroquinone or its derivatives, when sold in a concentration less than or equal to 2% in preparations for topical use on the skin

2 Hyoscine and its salts and derivatives [scopolamine] (except hyoscine butylbromide, when recommended for parenteral use)

2 Hyoscyamine and its salts and derivatives (except for topical use)

2 Iodine and its salts and derivatives (except topical preparations or in oral doses of 1 mg or less per day)

2 Ipecac and its extracts and derivatives (when used as an emetic)

2 Iron and its salts and derivatives (preparations with more than 30 mg elemental iron per solid dosage unit or 5 mL oral liquid)

2 Lobelia and its alkaloids and preparations (except internal preparations containing not more than 2 mg lobeline sulphate, external preparations containing not more than the equivalent of 400 mg of crude lobelia or preparations containing 130 mg or less of lobelia inflata)

2 Magnesium sulfate (for parenteral use)

2 Mannitol and its salts

2 Methenamine and its salts (except for topical use)

2 Methyl salicylate (in liquid dosage forms in concentrations greater than 30%)

2 Nicotinic acid [niacin] in extended-release formulations, except when sold in a modified-release oral dosage form that provides 500 mg or more per dosage unit or per daily dose

1 Nicotinyl-tartrate

2 Norepinephrine and its salts (levarterenol, noradrenaline)

2 Phenol (preparations with concentration of more than 20%)

2 Physostigmine salicylate (for oral or topical use)

2 Potassium salts (in oral preparations containing more than 5 mmol per single dose, except

(a) potassium bromide,

(b) potassium gluconate when sold or recommended for administration to cats,

(c) potassium para-aminobenzoate, and

(d) potassium citrate when recommended for the treatment of renal tubular acidosis and kidney stones)

2 Povidone - iodine (vaginal preparations, except in concentrations of 5% or less)

2 Pyrethrins (allethrins)

2 Pyrethrins (allethrins)/piperonyl butoxide

1 Quinidine salts

1 Quinine salts

2 Racemethionine

2 Rue and its preparations and extracts

2 Salicylic acid (when sold to be applied to warts, corns or calluses in topical preparations in concentrations greater than 40%)

2 Scopolamine and its salts (hyoscine)

2 Silver nitrate

2 Sodium acetate (for parenteral use)

2 Sodium biphosphate (for parenteral use)

2 Sodium chloride (single ingredient solutions for parenteral or ophthalmic use in concentrations of more than 0.9%) [NOTE: Does not apply to contact lens solutions intended to be rinsed off prior to insertion into eye]

2 Sodium citrate (for parenteral use)

2 Sodium iodide (for sclerosing)

2 Sodium phosphate (for parenteral use)

2 Stramonium and its preparations, extracts, and compounds

2 Strontium and its salts (for parenteral use)

2 Vitamins (any parenterals not otherwise scheduled in Schedule I)

2 Xylose , and

(b) by adding the following:

2 Acetylcysteine in injectable form

2 Allethrins

1 Alverine and its salts in injectable form

1 Amino acid solutions in injectable form

2 Benzocaine and its salts in injectable form

1 Bilastine or its salts or derivatives

3 Bisacodyl and its salts (except when sold in strengths of 5 mg or less per oral dosage unit in package sizes containing no more than 105 mg of bisacodyl and except when sold in strengths of 10 mg or less per rectal dosage unit/suppository in package sizes containing no more than 50 mg of bisacodyl)

2 Choline bitartrate in injectable form

2 Chymopapain in injectable form

2 Chymotrypsin in injectable form

2 Dextrose in injectable form, when used as a sclerosing agent

1 Epinephrine and its salts in injectable form, except in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens

1 Epinephrine or its salts, when sold as epinephrine topical solution for hemostasis at a concentration equal to or greater than 1 mg/ml (1:1000)

1 Esketamine

2 Heparin and its salts in injectable form

1 Hydroquinone or its derivatives, when sold in a concentration greater than 2% in preparations for topical use on the skinV

2 Hyoscine butylbromide (Butylscopolamine bromide), except when recommended for injectable use

2 Hyoscine (scopolamine) in injectable form

2 Magnesium sulfate in injectable form

2 Norepinephrine and its salts (levarterenol, noradrenaline) in injectable form

2 Piperonyl butoxide

1 Quinine or its salts or derivatives, except when sold in oral dosage form that provides 50 milligrams or less of quinine base per dosage unit or per daily dose

2 Sodium acetate in injectable form

2 Sodium biphosphate in injectable form

2 Sodium chloride, single ingredient solutions for injectable use in concentrations of more than 0.9%

2 Sodium citrate in injectable form

2 Sodium iodide in injectable form, when used as a sclerosing agent

2 Sodium phosphate in injectable form

2 Strontium and its salts in injectable form

2 Vitamins in injectable form, except those listed in Schedule I .


Copyright © 2022: Queen's Printer, Victoria, British Columbia, Canada